About Achillion Pharmaceuticals (NASDAQ:ACHN)
Achillion Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes small molecule drug therapies for immune system disorders in the United States. Its lead drug candidate includes ACH-4471, an inhibitor of factor D that is Phase II clinical trials for patients with paroxysmal nocturnal hemoglobinuria and C3 glomerulopathy. The company is also developing ACH-5228, a factor D inhibitor that is in Phase I clinical trial; ACH-5548, a factor D inhibitor; and other factor D inhibitors. It has license agreements with GCA Therapeutics, Ltd and Ora, Inc., as well as a collaboration arrangement with Janssen Pharmaceuticals Inc. to develop and commercialize drug candidates for the treatment of chronic hepatitis C virus. The company was founded in 1998 and is headquartered in New Haven, Connecticut.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:ACHN
CUSIP00448Q20
Phone203-624-7000
Debt
Debt-to-Equity RatioN/A
Current Ratio23.60%
Quick Ratio23.60%
Price-To-Earnings
Trailing P/E Ratio-5.89
Forward P/E Ratio-6.64
P/E GrowthN/A
Sales & Book Value
Annual Sales$15 million
Price / Sales33.56
Cash FlowN/A
Price / CashN/A
Book Value$2.35 per share
Price / Book1.55
Profitability
EPS (Most Recent Fiscal Year)($0.62)
Net Income$-85,230,000.00
Net MarginsN/A
Return on Equity-24.09%
Return on Assets-23.22%
Miscellaneous
Employees88
Outstanding Shares137,900,000
Achillion Pharmaceuticals (NASDAQ:ACHN) Frequently Asked Questions
What is Achillion Pharmaceuticals' stock symbol?
Achillion Pharmaceuticals trades on the NASDAQ under the ticker symbol "ACHN."
How were Achillion Pharmaceuticals' earnings last quarter?
Achillion Pharmaceuticals (NASDAQ:ACHN) posted its quarterly earnings data on Thursday, February, 22nd. The biopharmaceutical company reported ($0.17) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.16) by $0.00. During the same period last year, the company posted ($0.03) earnings per share. View Achillion Pharmaceuticals' Earnings History.
When is Achillion Pharmaceuticals' next earnings date?
What guidance has Achillion Pharmaceuticals issued on next quarter's earnings?
Achillion Pharmaceuticals updated its FY18 earnings guidance on Thursday, February, 22nd. The company provided earnings per share guidance of ($0.58-0.55) for the period, compared to the Thomson Reuters consensus estimate of ($0.71).
What price target have analysts set for ACHN?
7 brokers have issued 12 month target prices for Achillion Pharmaceuticals' shares. Their predictions range from $3.50 to $7.00. On average, they expect Achillion Pharmaceuticals' share price to reach $5.00 in the next twelve months. View Analyst Ratings for Achillion Pharmaceuticals.
Who are some of Achillion Pharmaceuticals' key competitors?
Some companies that are related to Achillion Pharmaceuticals include MacroGenics (MGNX), Access Pharmaceuticals (ABEO), Biohaven Pharmaceutical (BHVN), Assembly Biosciences (ASMB), Alder BioPharmaceuticals (ALDR), Flexion Therapeutics (FLXN), Inflarx (IFRX), Amphastar Pharmaceuticals (AMPH), Lexicon Pharmaceuticals (LXRX), Amarin (AMRN), ARMO BioSciences (ARMO), Mirati Therapeutics (MRTX), Eagle Pharmaceuticals (EGRX), Collegium Pharmaceutical (COLL), Deciphera Pharmaceuticals (DCPH), CymaBay Therapeutics (CBAY), Urogen Pharma (URGN) and OptiNose (OPTN).
Who are Achillion Pharmaceuticals' key executives?
Achillion Pharmaceuticals' management team includes the folowing people:
- Dr. Milind S. Deshpande, CEO & Director (Age 61)
- Mr. Joseph Truitt, Pres & COO (Age 53)
- Ms. Mary Kay Fenton, Exec. VP, CFO & Principal Accounting Officer (Age 54)
- Glenn Schulman, Exec. Director of Investor Relations
- Ms. Martha E. Manning, Exec. VP, Gen. Counsel & Corp. Sec. (Age 63)
Has Achillion Pharmaceuticals been receiving favorable news coverage?
News coverage about ACHN stock has trended somewhat positive this week, Accern reports. The research firm identifies positive and negative media coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Achillion Pharmaceuticals earned a media sentiment score of 0.10 on Accern's scale. They also assigned news coverage about the biopharmaceutical company an impact score of 45.81 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the next few days.
How do I buy shares of Achillion Pharmaceuticals?
Shares of ACHN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Achillion Pharmaceuticals' stock price today?
One share of ACHN stock can currently be purchased for approximately $3.65.
How big of a company is Achillion Pharmaceuticals?
Achillion Pharmaceuticals has a market capitalization of $503.32 million and generates $15 million in revenue each year. The biopharmaceutical company earns $-85,230,000.00 in net income (profit) each year or ($0.62) on an earnings per share basis. Achillion Pharmaceuticals employs 88 workers across the globe.
How can I contact Achillion Pharmaceuticals?
Achillion Pharmaceuticals' mailing address is 300 GEORGE STREET, NEW HAVEN CT, 06511. The biopharmaceutical company can be reached via phone at 203-624-7000.
MarketBeat Community Rating for Achillion Pharmaceuticals (ACHN)
MarketBeat's community ratings are surveys of what our community members think about Achillion Pharmaceuticals and other stocks. Vote "Outperform" if you believe ACHN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ACHN will underperform the S&P 500 over the long term. You may vote once every thirty days.
Achillion Pharmaceuticals (NASDAQ:ACHN) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
7 Wall Street analysts have issued ratings and price targets for Achillion Pharmaceuticals in the last 12 months. Their average twelve-month price target is $5.00, suggesting that the stock has a possible upside of 36.99%. The high price target for ACHN is $7.00 and the low price target for ACHN is $3.50. There are currently 4 hold ratings and 3 buy ratings for the stock, resulting in a consensus rating of "Hold."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Hold | Hold | Buy | Buy |
| Consensus Rating Score: | 2.43 | 2.43 | 2.50 | 2.57 |
| Ratings Breakdown: | 0 Sell Rating(s)
4 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
4 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
3 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
3 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $5.00 | $5.00 | $5.30 | $6.75 |
| Price Target Upside: | 36.99% upside | 71.23% upside | 80.58% upside | 74.87% upside |
Achillion Pharmaceuticals (NASDAQ:ACHN) Consensus Price Target History
Achillion Pharmaceuticals (NASDAQ:ACHN) Analyst Ratings History
Show:
(Data available from 4/23/2016 forward)
Achillion Pharmaceuticals (NASDAQ:ACHN) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Achillion Pharmaceuticals (NASDAQ ACHN) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 7.24%
Institutional Ownership Percentage: 82.04%
Achillion Pharmaceuticals (NASDAQ ACHN) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 11/20/2017 | & Johnson Johnson | Major Shareholder | Sell | 18,367,346 | $2.75 | $50,510,201.50 | |  |
| 12/22/2016 | Jason S Fisherman | Director | Buy | 10,000 | $3.96 | $39,600.00 | 50,000 | |
| 12/5/2016 | Mary Kay Fenton | CFO | Buy | 2,500 | $4.11 | $10,275.00 | 2,500 | |
| 12/2/2016 | Joel C Barrish | Insider | Buy | 2,500 | $4.06 | $10,150.00 | 2,500 | |
| 12/30/2015 | David Apelian | insider | Sell | 10,000 | $10.50 | $105,000.00 | | |
| 12/28/2015 | Mary Kay Fenton | CFO | Sell | 43,500 | $10.08 | $438,480.00 | | |
| 11/11/2015 | Nicole Vitullo | Director | Sell | 550,000 | $10.17 | $5,593,500.00 | 31,431 | |
| 9/25/2015 | Nicole Vitullo | Director | Sell | 9,310 | $8.22 | $76,528.20 | 31,431 | |
| 1/23/2015 | Mary Kay Fenton | CFO | Sell | 13,125 | $16.00 | $210,000.00 | | |
| 1/21/2015 | Milind Deshpande | CEO | Sell | 100,000 | $15.00 | $1,500,000.00 | | |
| 9/30/2014 | Ra Capital Management, Llc | Insider | Sell | 1,332,014 | $10.20 | $13,586,542.80 | | |
| 9/29/2014 | Ra Capital Management, Llc | Insider | Sell | 221,014 | $10.96 | $2,422,313.44 | | |
| 9/26/2014 | Ra Capital Management, Llc | Major Shareholder | Sell | 2,372,915 | $11.17 | $26,505,460.55 | | |
| 9/25/2014 | Ra Capital Management, Llc | Major Shareholder | Sell | 497,986 | $11.05 | $5,502,745.30 | | |
| 9/24/2014 | Ra Capital Management, Llc | Major Shareholder | Sell | 1,204,929 | $11.27 | $13,579,549.83 | | |
| 9/23/2014 | Ra Capital Management, Llc | Major Shareholder | Sell | 2,595,071 | $11.29 | $29,298,351.59 | | |
| 9/2/2014 | Ra Capital Management, Llc | Major Shareholder | Sell | 835,293 | $11.63 | $9,714,457.59 | | |
| 8/27/2014 | Ra Capital Management, Llc | Major Shareholder | Sell | 2,711,352 | $11.33 | $30,719,618.16 | | |
| 8/26/2014 | Ra Capital Management, Llc | Major Shareholder | Sell | 2,112,867 | $11.35 | $23,981,040.45 | | |
| 8/25/2014 | Joseph Truitt | EVP | Sell | 25,000 | $10.82 | $270,500.00 | | |
| 8/25/2014 | Ra Capital Management, Llc | Major Shareholder | Sell | 331,396 | $10.96 | $3,632,100.16 | | |
| 8/18/2014 | Milind Deshpande | CEO | Sell | 216,624 | $10.00 | $2,166,240.00 | | |
| 8/18/2014 | Ra Capital Management, Llc | Major Shareholder | Sell | 4,235,000 | $9.53 | $40,359,550.00 | | |
| 8/15/2014 | Michael D Kishbauch | Director | Sell | 495,812 | $9.40 | $4,660,632.80 | | |
| 8/13/2014 | Gary E Frashier | Director | Sell | 5,000 | $8.00 | $40,000.00 | | |
| 6/20/2014 | Ra Capital Management, Llc | Insider | Sell | 880,000 | $8.40 | $7,392,000.00 | | |
| 6/16/2014 | Gary E Frashier | Director | Sell | 55,000 | $8.00 | $440,000.00 | | |
| 6/16/2014 | Joseph Truitt | EVP | Sell | 25,000 | $7.82 | $195,500.00 | | |
| 6/16/2014 | Qvt Associates Gp Llc | Major Shareholder | Sell | 1,819,551 | $7.70 | $14,010,542.70 | | |
| 6/11/2014 | Qvt Associates Gp Llc | Major Shareholder | Sell | 128,649 | $7.66 | $985,451.34 | | |
| 6/10/2014 | Joseph Truitt | EVP | Sell | 50,000 | $6.02 | $301,000.00 | | |
| 6/10/2014 | Michael D Kishbauch | Director | Sell | 371,937 | $7.75 | $2,882,511.75 | | |
| 12/30/2013 | Qvt Associates Gp Llc | major shareholder | Sell | 170,239 | $3.34 | $568,598.26 | | |
| 12/26/2013 | Qvt Associates Gp Llc | major shareholder | Sell | 121,205 | $3.44 | $416,945.20 | | |
| 12/23/2013 | Qvt Associates Gp Llc | major shareholder | Sell | 289,141 | $3.24 | $936,816.84 | | |
| 12/19/2013 | Qvt Associates Gp Llc | major shareholder | Sell | 222,612 | $3.09 | $687,871.08 | | |
| 12/17/2013 | Qvt Associates Gp Llc | major shareholder | Sell | 92,803 | $3.11 | $288,617.33 | | |
| 11/22/2013 | Dennis Liotta | Director | Buy | 10,000 | $2.98 | $29,800.00 | 100,000 | |
| 11/20/2013 | Ra Capital Management, Llc | Insider | Buy | 1,110,000 | $2.55 | $2,830,500.00 | | |
| 11/19/2013 | Jason Fisherman | Director | Buy | 15,000 | $2.63 | $39,450.00 | 40,000 | |
| 11/12/2013 | Ra Capital Management, Llc | Insider | Buy | 1,795,000 | $2.48 | $4,451,600.00 | | |
| 10/31/2013 | Ra Capital Management, Llc | Insider | Buy | 1,186,007 | $2.45 | $2,905,717.15 | | |
| 10/14/2013 | Ra Capital Management, Llc | Insider | Buy | 2,369,229 | $2.79 | $6,610,148.91 | | |
| 10/11/2013 | Ra Capital Management, Llc | Insider | Buy | 2,448,710 | $2.56 | $6,268,697.60 | | |
| 9/30/2013 | Ra Capital Management, Llc | Insider | Buy | 2,800,000 | $2.98 | $8,344,000.00 | | |
| 8/14/2013 | Jason Fisherman | Director | Buy | 5,000 | $6.83 | $34,150.00 | 25,000 | |
| 8/12/2013 | Dennis Liotta | Director | Buy | 5,000 | $6.47 | $32,350.00 | 90,000 | |
| 8/9/2013 | Qvt Associates Gp Llc | major shareholder | Buy | 102,282 | $6.41 | $655,627.62 | | |
| 7/11/2013 | Qvt Associates Gp Llc | Major Shareholder | Buy | 401,017 | $6.46 | $2,590,569.82 | | |
| 7/10/2013 | Qvt Associates Gp Llc | Major Shareholder | Buy | 390,944 | $6.33 | $2,474,675.52 | | |
| 7/8/2013 | Qvt Associates Gp Llc | Major Shareholder | Buy | 642,509 | $6.28 | $4,034,956.52 | | |
| 7/3/2013 | Qvt Associates Gp Llc | Major Shareholder | Buy | 1,963,248 | $6.43 | $12,623,684.64 | | |
| 7/1/2013 | Gary E Frashier | Director | Sell | 5,000 | $8.17 | $40,850.00 | | |
| 6/21/2013 | Jason S Fisherman | Director | Buy | 10,000 | $7.63 | $76,300.00 | | |
| 6/7/2013 | Gary E Frashier | Director | Sell | 5,000 | $8.37 | $41,850.00 | | |
| 6/3/2013 | Jason S Fisherman | Director | Buy | 10,000 | $7.87 | $78,700.00 | | |
(Data available from 1/1/2013 forward)
Achillion Pharmaceuticals (NASDAQ ACHN) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | Achillion Pharmaceuticals (ACHN) Downgraded by BidaskClub
www.americanbankingnews.com - April 18 at 6:54 PM |
| Achillion Pharmaceuticals (ACHN) Expected to Announce Earnings of -$0.14 Per Share
www.americanbankingnews.com - April 18 at 5:18 PM |
| Achillion Pharmaceuticals (ACHN) Receives Consensus Recommendation of "Hold" from Brokerages
www.americanbankingnews.com - April 18 at 9:15 AM |
| Achillion Pharmaceuticals (ACHN) Stock Rating Lowered by BidaskClub
www.americanbankingnews.com - April 16 at 12:02 PM |
 | Investor Expectations to Drive Momentum within Credicorp, Essent Group, Achillion Pharmaceuticals, Banco Santander, S.A, Check Point Software Technologies, and Fomento Economico Mexicano S.A.B. de C.V — Discovering Underlying Factors of Influence
finance.yahoo.com - April 9 at 8:41 AM |
| Achillion Pharmaceuticals' (ACHN) Neutral Rating Reiterated at Robert W. Baird
www.americanbankingnews.com - April 8 at 11:23 PM |
| Achillion Pharmaceuticals (ACHN) Cut to "Hold" at BidaskClub
www.americanbankingnews.com - April 3 at 8:57 AM |
| Achillion Pharmaceuticals, Inc. (ACHN) Expected to Announce Earnings of -$0.14 Per Share
www.americanbankingnews.com - April 1 at 5:10 PM |
| Achillion Pharmaceuticals (ACHN) Downgraded by Zacks Investment Research
www.americanbankingnews.com - April 1 at 12:40 AM |
| Achillion Pharmaceuticals (ACHN) Lowered to "Hold" at Zacks Investment Research
www.americanbankingnews.com - March 31 at 11:46 AM |
| BidaskClub Upgrades Achillion Pharmaceuticals (ACHN) to "Sell"
www.americanbankingnews.com - March 25 at 3:47 PM |
| BidaskClub Upgrades Achillion Pharmaceuticals (ACHN) to "Buy"
www.americanbankingnews.com - March 24 at 1:36 PM |
| Achillion Pharmaceuticals, Inc. (ACHN) Receives Consensus Rating of "Hold" from Analysts
www.americanbankingnews.com - March 24 at 9:18 AM |
 | Are Options Traders Betting on a Big Move in Achillion Pharmaceuticals (ACHN) Stock?
www.zacks.com - March 20 at 8:46 AM |
 | Achillion Pharmaceuticals (ACHN) Presents At Barclays Global Healthcare Conference 2018 - Slideshow
seekingalpha.com - March 16 at 6:14 PM |
| -$0.14 EPS Expected for Achillion Pharmaceuticals, Inc. (ACHN) This Quarter
www.americanbankingnews.com - March 15 at 1:51 PM |
| Achillion Pharmaceuticals, Inc. (ACHN) Short Interest Update
www.americanbankingnews.com - March 11 at 1:58 AM |
 | Achillion to Present at the Barclays Global Healthcare Conference - Nasdaq
www.nasdaq.com - March 8 at 8:40 AM |
| Emory University Has $1.49 Million Holdings in Achillion Pharmaceuticals, Inc. (ACHN)
www.americanbankingnews.com - March 4 at 3:02 PM |
| Spark Investment Management LLC Buys 422,800 Shares of Achillion Pharmaceuticals, Inc. (ACHN)
www.americanbankingnews.com - March 2 at 12:29 PM |
| Achillion Pharmaceuticals (ACHN) Stock Rating Upgraded by Zacks Investment Research
www.americanbankingnews.com - February 27 at 12:39 PM |
| Achillion Pharmaceuticals (ACHN) Soars: Stock Adds 15.4% in Session
www.zacks.com - February 27 at 8:37 AM |
| Why Achillion Pharmaceuticals, Inc. Stock Spiked Today
finance.yahoo.com - February 27 at 8:37 AM |
| Today’s Research Reports on Trending Tickers: Achillion Pharmaceuticals and Novavax
finance.yahoo.com - February 27 at 8:37 AM |
| Achillion Pharmaceuticals, Inc. (ACHN) Receives Average Recommendation of "Hold" from Brokerages
www.americanbankingnews.com - February 27 at 7:36 AM |
 | Mid-Afternoon Market Update: Telaria Falls Following Q4 Results; Achillion Pharmaceuticals Shares Surge
feeds.benzinga.com - February 26 at 4:17 PM |
| Achillion Pharmaceuticals, Inc. (ACHN) Expected to Post Earnings of -$0.16 Per Share
www.americanbankingnews.com - February 26 at 1:16 PM |
| Achillion (ACHN) Q4 Loss Widens, Plans Job Cuts to Save Cost
www.zacks.com - February 23 at 8:39 AM |
 | Form 8-K ACHILLION PHARMACEUTICAL For: Feb 22
www.streetinsider.com - February 22 at 5:27 PM |
| Was Achillion Pharmaceuticals Inc’s (NASDAQ:ACHN) Earnings Decline A Part Of Broader Industry Downturn?
finance.yahoo.com - February 22 at 5:27 PM |
| Achillion Pharmaceuticals (ACHN) Announces Quarterly Earnings Results, Misses Estimates By $0.01 EPS
www.americanbankingnews.com - February 22 at 10:50 AM |
| Achillion Pharmaceuticals (ACHN) Updates FY18 Earnings Guidance
www.americanbankingnews.com - February 22 at 10:09 AM |
| Achillion Pharmaceuticals (ACHN) Upgraded by BidaskClub to "Hold"
www.americanbankingnews.com - February 19 at 3:38 PM |
| Achillion to Present at the Leerink Partners 7th Annual Global Healthcare Conference
finance.yahoo.com - February 17 at 8:25 AM |
| Achillion Pharmaceuticals, Inc. Expected to Earn FY2017 Earnings of ($0.59) Per Share (ACHN)
www.americanbankingnews.com - February 12 at 1:08 AM |
| Achillion Pharmaceuticals (ACHN) Research Coverage Started at B. Riley
www.americanbankingnews.com - February 11 at 3:24 PM |
| Achillion Pharmaceuticals, Inc. (ACHN) Receives Average Rating of "Hold" from Analysts
www.americanbankingnews.com - February 2 at 12:34 PM |
| Achillion Pharmaceuticals, Inc. (ACHN) Expected to Announce Earnings of -$0.15 Per Share
www.americanbankingnews.com - January 23 at 11:06 PM |
| Achillion Pharmaceuticals: Ultra-Rare Disease Company With Ultra-Rare Enterprise Value - Seeking Alpha
seekingalpha.com - January 10 at 6:36 AM |
| Achillion Pharmaceuticals, Inc. (ACHN) Given Consensus Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - January 8 at 8:38 AM |
 | Technical Perspectives on Cytokinetics, Geron, Achillion Pharma, and Calithera Biosciences - PR Newswire (press release)
www.prnewswire.com - December 29 at 9:24 AM |
| Alexion's (ALXN) Soliris Label Expansion Approved in Japan
finance.yahoo.com - December 27 at 9:54 AM |
| BioMarin's (BMRN) Pegvaliase Review Period Extended by FDA
finance.yahoo.com - December 26 at 11:29 PM |
| Achillion Pharmaceuticals (ACHN) Raised to "Sell" at BidaskClub
www.americanbankingnews.com - December 23 at 5:04 PM |
| CORRECTION - Achillion Pharmaceuticals, Inc.
finance.yahoo.com - December 20 at 3:18 PM |
| Achillion Pharma (ACHN) Commences Phase I First-In Study of ACH-5228 - StreetInsider.com
www.streetinsider.com - December 20 at 6:15 AM |
| Achillion Initiates Phase I First-In Study of ACH-5228, a Next-Generation Oral Small Molecule Inhibitor of Complement Factor D
finance.yahoo.com - December 20 at 6:15 AM |
| Achillion's Renal Disease Candidate Gets Orphan Drug Status
www.nasdaq.com - December 19 at 3:18 PM |
| Achillion Pharma (ACHN) Granted FDA Orphan Drug Designation for ACH-4471 & Initiation of Phase 1 Extended ... - StreetInsider.com
www.streetinsider.com - December 19 at 6:30 AM |
| Twitter Up 5% on Better Rating
finance.yahoo.com - December 18 at 3:18 PM |
Achillion Pharmaceuticals (NASDAQ:ACHN) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Achillion Pharmaceuticals (NASDAQ:ACHN) Income Statement, Balance Sheet and Cash Flow Statement
Achillion Pharmaceuticals (NASDAQ ACHN) Stock Chart for Monday, April, 23, 2018
Loading chart…
